Clinical Report: The Case for Simulating Pregnancy

Overview

This report discusses the critical role of pharmacokinetic modeling in addressing gaps in drug use during pregnancy. It highlights the need for better data to inform treatment decisions for pregnant women, who are often excluded from clinical trials.

Background

The exclusion of pregnant women from clinical trials has led to a significant lack of data regarding drug dosing and safety during pregnancy. This gap creates uncertainty for healthcare providers and patients alike, as treatment decisions must often be made without adequate evidence. Understanding the physiological changes during pregnancy that affect drug metabolism is essential for optimizing treatment and ensuring maternal and fetal health.

Data Highlights

Key Findings

• Pregnant women are frequently excluded from clinical trials, leading to limited data on drug safety and efficacy.
• Physiological changes during pregnancy can significantly alter drug metabolism, necessitating tailored dosing strategies.
• Pharmacokinetic modeling can help fill data gaps and support informed treatment decisions for pregnant women.
• Regulatory agencies are increasingly accepting simulation data to complement clinical data in drug development.
• Conditions like preeclampsia require timely intervention, highlighting the need for evidence-based treatment guidelines.

Clinical Implications

Healthcare providers must recognize the limitations of existing drug data for pregnant patients and consider pharmacokinetic modeling as a tool to inform dosing. Increased collaboration with regulatory agencies can facilitate the inclusion of pregnant women in clinical research, ultimately improving treatment outcomes.

Conclusion

Pharmacokinetic modeling represents a promising approach to address the lack of data on drug use during pregnancy. By enhancing our understanding of drug behavior in this population, we can improve clinical decision-making and patient care.

Related Resources & Content

1. American Journal of Epidemiology, 2023 -- A novel approach for inferring effects on pregnancy loss
2. A Comprehensive Sensing Mixed-Reality Trainer for Minimally Invasive Fetal Laser Surgery, 2018
3. Drug Safety, 2025 -- Evaluating the VigiBase Pregnancy Algorithm for Identifying Pregnancy Exposures in Pharmacovigilance Databases: A Detailed Assessment
4. npj Digital Medicine, 2025 -- Integrated Predictive Model for In Vitro Fertilization Outcomes
5. E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials | FDA, 2025
6. Treating Pregnant and Lactating Women: Insights from Clinical Pharmacology | Annual Reviews, 2026
7. Appendix B: Dolutegravir (Tivicay, Tivicay PD) - Safety and Toxicity in Pregnancy | NIH
8. E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials | FDA
9. Treating Pregnant and Lactating Women: Insights from Clinical Pharmacology | Annual Reviews
10. Appendix B: Dolutegravir (Tivicay, Tivicay PD) - Safety and Toxicity in Pregnancy | NIH